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Investments to reduce the spread of antimicrobial 
resistance (AMR) in the European Union have been 
made, including efforts to strengthen prudent anti-
microbial use. Using segmented regression, we 
report decreasing and stabilising trends in data 
reported to the European Surveillance of Antimicrobial 
Consumption Network and stabilising trends in data 
reported to the European Antimicrobial Resistance 
Surveillance Network. Our results could be an early 
indication of the effect of prioritising AMR on the pub-
lic health agenda.
Antimicrobial resistance (AMR) is one of the main 
public health challenges worldwide. In the European 
Union (EU) and European Economic Area (EEA), 33,000 
deaths are estimated to be attributed to infections with 
AMR bacteria annually [1]. Ensuring prudent antimicro-
bial use is key to an effective response to AMR, as 
antimicrobial use exerts ecological pressure on bacte-
ria and contributes to the emergence and selection of 
resistant bacteria. Here, we describe trends in antimi-
crobial consumption of fluoroquinolones, third-gener-
ation cephalosporins and carbapenems between 2001 
and 2018 and for AMR in Escherichia coli and Klebsiella 
pneumoniae.
Initiatives targeting antimicrobial 
resistance in EU/EEA
The European Antibiotic Awareness Day, a European 
health initiative and annual event coordinated by the 
European Centre for Disease Prevention and Control 
(ECDC), was initiated in 2008 to support EU/EEA coun-
tries in their efforts to prevent and control AMR by 
raising awareness about prudent use of antibiotics [2]. 
Several EU and global initiatives followed, all prompt-
ing action at EU/EEA and at country level. Among these 
were: (i) a first EU Action Plan against the rising threat 
from AMR in 2011 [3], (ii) a World Health Organization 
Global Action Plan on AMR in 2015 [4], (iii) EU Guidelines 
for the prudent use of antimicrobials in human health 
[5] (iv) a new European One Health Action Plan against 
AMR in 2017 [6], and (v) various Council Conclusions 
adopted by EU Member States between 2008 and 2019 
[7]. If successful, these efforts should be reflected in 
the trends of antimicrobial consumption and of corre-
sponding AMR levels in the EU/EEA.
Analysis of antimicrobial consumption and 
antimicrobial resistance trends
To examine trends, we analysed population-weighted 
EU/EEA-wide data from the European Surveillance 
of Antimicrobial Consumption Network (ESAC-Net, 
formerly ESAC) and the European Antimicrobial 
Resistance Surveillance Network (EARS-Net, formerly 
EARSS). Using joinpoint version 4.7.0.0 (National 
Cancer Institute, Bethesda, United States), we per-
formed a regression analysis of data reported to ESAC-
Net/ESAC on defined daily doses (DDDs) as listed in 
the Anatomical Therapeutic Chemical (ATC) Index for 
2019 [8] on the consumption of fluoroquinolones (ATC 
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group J01MA), third-generation cephalosporins (ATC 
group J01DD) and carbapenems (ATC group J01DH) in 
the community and hospital sector between 2001 and 
2018. Using data from EARS-Net/EARSS, corresponding 
AMR percentages in invasive  E. coli  (2002–18) and  K. 
pneumoniae  (2006–18) isolates were analysed with 
the same joinpoint methodology.  E. coli  and  K. pneu-
moniae are among the pathogens contributing most to 
the burden of AMR in the EU/EAA [1] and for which AMR 
levels have increased substantially during the last dec-
ades [9-12]. Joinpoint regression is a time series analy-
sis technique that is especially useful when the slope 
of the regression function is expected to change over 
time, as it allows the analyses to identify the points in 
time at which trends change and to characterise seg-
ments in the time series [13]. Materials and methods 
are detailed in the  Supplementary Material, including 
an additional sensitivity analysis.
Trends in EU/EEA population-weighted 
antimicrobial consumption
For antimicrobial consumption, the joinpoint model 
identified two separate trend segments for third-gener-
ation cephalosporin consumption (Table 1, Figure 1 and 
three separate trend segments for fluoroquinolone and 
carbapenem consumption during 2001–2018 (Table 
1,  Figure 2  and  Figure 3). For the purpose of this arti-
cle, we use the terms ‘increase’ or ‘decrease’ when 
the trend of the segment was statistically significant 
(p ≤ 0.05) and we used the term ‘stable’ when there was 
no statistically significant trend (p > 0.05).
The most recent trend segments, starting between 
2008 and 2016 depending on the antimicrobial group 
and sector, all showed stable or decreasing trends, 
while segments covering earlier years showed larger 
variation (Table 1,  Figures 1-3). For consumption of 
third-generation cephalosporins in hospital sector 
(Table 1,  Figure 1) and carbapenems in the hospital 
sector (Table 1,  Figure 3), the most recent segments 
showed stable levels whereas previous segments 
Table 1
Joinpoint regression analysis of trends: EU/EEA population-weighted mean consumption expressed in DDD per 1000 
inhabitants per day, per antimicrobial group and sector, ESAC-Net/ESAC, 2001–2018
Segment
Lower endpoint Upper endpoint APC
Year 95% CI Year 95% CI APC (%) 95% CI P value
Third-generation cephalosporin consumption (ATC group J01DD)
Community sector
All years 2001 NA 2018 NA -0.6 -1.2 to -0.1 0.033
Segment 1 2001 NA 2010 2008 to 2013  + 0.7 -0.04 to 1.5 0.062
Segment 2 2010 2008 to 2013 2018 NA -2.1 -3.0 to -1.2   < 0.001
Hospital sector
All years 2001 NA 2018 NA   + 4.3 0.8 to 7.8 0.015
Segment 1 2001 NA 2010 2003 to 2015   + 9.0 3.8 to 14.5 0.002
Segment 2 2010 2003 to 2015 2018 NA -0.9 -6.3 to 4.9 0.746
Fluoroquinolone consumption (ATC group J01MA)
Community sector
All years 2001 NA 2018 NA  + 0.1 -0.8 to 1.0 0.780
Segment 1 2001 NA 2008 2005 to 2013   + 2.5 1.5 to 3.6   < 0.001
Segment 2 2008 2005 to 2013 2016 2012 to 2016 -0.1 -1.2 to 0.9 0.760
Segment 3 2016 2012 to 2016 2018 NA -6.8 -12.8 to -0.4 0.040
Hospital sector
All years 2001 NA 2018 NA  + 2.0 -1.9 to 5.9 0.318
Segment 1 2001 NA 2003 2003 to 2005   + 34.3 1.0 to 78.5 0.044
Segment 2 2003 2003 to 2005 2008 2006 to 2016  + 2.1 -6.2 to 11.2 0.598
Segment 3 2008 2006 to 2016 2018 NA -3.6 -5.5 to -1.6 0.003
Carbapenem consumption (ATC group J01DH)
Hospital sector
All years 2001 NA 2018 NA   + 9.2 3.8 to 14.7 0.001
Segment 1 2001 NA 2003 2003 to 2012   + 46.9 4.2 to 107.0 0.032
Segment 2 2003 2003 to 2012 2013 2006 to 2016   + 9.2 4.4 to 14.2 0.001
Segment 3 2013 2006 to 2016 2018 NA -3.1 -12.4 to 7.2 0.500
APC: annual percentage change; CI: confidence interval; DDD: defined daily doses; ESAC-Net/ESAC: European Surveillance of Antimicrobial 
Consumption Network/European Surveillance Antimicrobial Consumption project; NA: not applicable.
Statistically significant trends are shown in bold.
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showed increasing trends. For consumption of third-
generation cephalosporins in the community (Table 
1, Figure 1) as well as consumption of fluoroquinolones 
in both sectors (Table 1, Figure 2), the most recent seg-
ments showed a decreasing trend.
Trends EU/EEA-population weighted 
antimicrobial resistance percentages
The joinpoint model identified three separate trend 
segments for  E. coli  (Table 2,  Figures 1-2), and two 
trend segments for  K. pneumoniae  (Table 2,  Figures 
1-3). The most recent segments, starting between 2012 
and 2013 depending on the microorganism-antimi-
crobial group combination, showed more favourable 
trends, i.e. a stable level (fluoroquinolone resistance 
in  E. coli  and  K. pneumoniae, third-generation cepha-
losporin resistance and carbapenem resistance in  K. 
pneumoniae) or an increase but with a smaller slope 
compared with previous segments (third-generation 
cephalosporin resistance in E. coli) (Table 2). For almost 
all microorganism/antimicrobial group combinations, 
the reduction and/or stabilisation of antimicrobial con-
sumption started before or the same year as the trend 
in AMR stabilised (Figures 1-3).
Discussion
The decreasing or stabilising EU/EEA trends in antimi-
crobial consumption of fluoroquinolones, third-gener-
ation cephalosporins and carbapenems described in 
this study during the last 6–10 years could be an early 
signal of the positive effects of antimicrobial steward-
ship initiatives in EU/EEA countries. Although the eco-
logical study design and different data sources used 
cannot demonstrate a causal relationship between 
Figure 1
Consumption of third-generation cephalosporins by 
sector and third-generation cephalosporin resistance by 
microorganism, including detected trend segments, EU/
EEA population-weighted means, 2001–2018
A. Consumption of third-generation cephalosporins, J01DD
B. Resistance to third-generation cephalosporins
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Year
Year
DDD: defined daily doses; EU/EEA: European Union and European 
Economic Area.
Antimicrobial consumption trend segments are shown in red. AMR 
trend segments are shown in blue.
Figure 2
Consumption of fluoroquinolones by sector, and 
fluoroquinolone resistance by microorganism, including 
detected trend segments, EU/EEA population-weighted 
means, 2001–2018
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antimicrobial consumption and AMR, the similar, but 
less pronounced, stabilising trends or change in slope 
of AMR percentages are encouraging. Our analysis 
shows that the increase in AMR in E. coli and K. pneu-
moniae was most prominent up to 2012/13, after which 
there is a tendency towards stabilising levels. These 
trends may be less discernible in shorter time series 
analyses and underline the usefulness of data retrieved 
from longer reporting periods.
Our study has several limitations. First, for EARS-Net/
EARSS, we could not control for changes in the use of 
clinical breakpoints over time [14]. However, changes 
have generally been towards lower breakpoints, 
which would result in increasing AMR percentages 
rather than the stabilising trends we report. Second, 
although there are no indications of major changes 
in the frequency of blood culture sampling during the 
study period [15,16], other changes, e.g. in the popula-
tion under surveillance cannot be excluded and could 
have influenced the results. For ESAC-Net/ESAC, most 
countries provided sales data, but a few were only able 
to provide reimbursement data which do not include 
antimicrobials dispensed without a prescription or pre-
scribed antimicrobials for which reimbursement was 
not claimed [17]. Finally, for antimicrobial prescriptions, 
no information was available on the pathogen and its 
AMR profile. This could have allowed for identification 
of the factors and reasons for the observed trends in 
antimicrobial consumption.
Several other factors than consumption of specific anti-
microbial groups may have affected the corresponding 
AMR trends. The antimicrobial groups included in this 
study were selected as they are of relevance to treat 
severe infections caused by  E. coli  and  K. pneumo-
niae,  but they only contribute to approximately 14% 
of the total consumption of antibacterials for sys-
temic use (ATC group J01) (Supplementary Material). 
Combined resistance to multiple antimicrobial groups 
increased during our study period, especially for  K. 
pneumoniae  [12]. Consequently, one antimicro-
bial agent could also select co-resistant isolates.  In 
addition, changes in infection prevention and control 
(IPC) practices in hospitals and other healthcare 
settings in EU/EEA countries during the study period 
could have affected AMR trends, in particular for  K. 
pneumoniae  for which most infections are healthcare-
associated. Longitudinal data on IPC in hospitals in 
the EU/EEA are not available to analyse such potential 
impact. Finally, the trends presented here represent 
the population-weighted mean for the EU/EEA as a 
whole and individual countries may report different 
long-term trends and changes, therefore, each EU/EEA 
country should assess its own situation.
Conclusion
Responding to the increasing public health threat of 
AMR is a priority in the EU [3,6,7]. The trends of anti-
microbial consumption of fluoroquinolones, third-
generation cephalosporins and carbapenems and the 
AMR phenotypes reported here provide an indication 
that the recent public health efforts promoting prudent 
antimicrobial use are showing results. Nevertheless, 
percentages of AMR reported here were comparatively 
much higher in 2018 than in 2002/06 and trends appear 
to stabilise or slow down rather than decrease in recent 
years. The results presented should encourage further 
efforts aiming to improve antimicrobial stewardship 
and IPC, which should contribute to reduce AMR in the 
EU/EEA.
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Figure 3
Consumption of carbapenems in the hospital sector 
and carbapenems resistance in Klebsiella pneumoniae, 
including detected trend segments, EU/EEA population-
weighted means, 2001–2018
A. Consumption of carbapenems, J01DH 
B. Resistance to carbapenems
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DDD: defined daily doses; EU/EEA: European Union and European 
Economic Area.
a Carbapenem resistance in E. coli was not included. Because 
carbapenem resistance is rare in E. coli isolates in the EU/
EEA, carbapenem susceptibility is in many cases not routinely 
determined for this species in clinical microbiology laboratories.
Antimicrobial consumption trend segments are shown in red. AMR 
trend segments are shown in blue.
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of Antimicrobial Resistance (ISKRA), Croatia; Denmark: 
Karoline SKJOLD SELLE PEDERSEN, Statens Serum Institut, 
Copenhagen, Denmark; Estonia: Elviira LINASK, Bureau 
of Statistics, Department of Post-authorisation Safety, 
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of Szeged Department of Clinical Pharmacy, Hungary; 
Finland: Emmi SARVIKIVI, Finnish Institute for Health 
and Welfare, Helsinki, Finland; France; Philippe CAVALIÉ, 
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Department of Pharmacy, Radboud University Medical Center, 
Nijmegen, the Netherlands; Norway: Hege Salvesen BLIX, 
Department of Drug Statistics, Norwegian Institute of Public 
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National Medicines Institute, Department of Epidemiology 
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Table 2
Joinpoint regression analysis of trends: EU/EEA population-weighted mean percentage of resistance, by microorganism and 
antimicrobial group, EARS-Net/EARSS, 2002–2018
Segment
Lower endpoint Upper endpoint APC
Year 95% CI Year 95% CI APC (%) 95% CI P value
Escherichia coli
Third-generation cephalosporin resistance
All years 2002 NA 2018 NA   + 10.6 9.7 to 11.5   < 0.001
Segment 1 2002 NA 2006 2005 to 2008   + 21.8 19.0 to 24.7   < 0.001
Segment 2 2006 2005 to 2008 2012 2011 to 2014   + 12.4 10.7 to 14.2   < 0.001
Segment 3 2012 2011 to 2014 2018 NA   + 2.0 0.8 to 3.2 0.004
Fluoroquinolone resistance
All years 2002 NA 2018 NA   + 4.4 3.8 to 5.0   < 0.001
Segment 1 2002 NA 2006 2005 to 2007   + 14.9 13.0 to 16.8   < 0.001
Segment 2 2006 2005 to 2007 2012 2009 to 2015   + 2.0 1.0 to 3.1 0.002
Segment 3 2012 2009 to 2015 2018 NA  + 0.2 -0.6 to 1.0 0.538
Klebsiella pneumoniae
Third-generation cephalosporin resistance
All years 2006 NA 2018 NA   + 4.0 2.4 to 5.6   < 0.001
Segment 1 2006 NA 2013 2011 to 2016   + 6.7 4.6 to 8.8   < 0.001
Segment 2 2013 2011 to 2016 2018 NA  + 0.4 -2.9 to 3.8 0.809
Fluoroquinolone resistance
All years 2006 NA 2018 NA   + 5.8 3.1 to 8.6 0.001
Segment 1 2006 NA 2013 2009 to 2016   + 9.6 5.7 to 13.6   < 0.001
Segment 2 2013 2009 to 2016 2018 NA  + 0.8 -4.4 to 6.2 0.748
Carbapenem resistance
All years 2006 NA 2018 NA   + 19.6 10.5 to 29.4   < 0.001
Segment 1 2006 NA 2013 2010 to 2016   + 34.8 21.4 to 49.7   < 0.001
Segment 2 2013 2010 to 2016 2018 NA  + 1.0 -14.7 to 19.7 0.891
APC: annual percentage change; CI: confidence interval; EARS-Net/EARSS: European Antimicrobial Resistance Surveillance Network/European 
Antimicrobial Resistance Surveillance System; NA: not applicable.
Statistically significant trends are shown in bold.
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Bucharest, Romania; Slovakia: Eva SCHRETEROVA, Louis 
Pasteur University Hospital Kosice, Kosice, Slovakia; 
Slovenia: Helena RIBIČ, National Institute of Public Health, 
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